Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9289504
Single protein nanocapsules for protein delivery with long-term effect
granted -
US 9290539
Melanotropin ligands for skin care
granted -
US 9283185
Liposomal curcumin for treatment of cancer
granted -
US 9284546
Human cystathionine beta-synthase variants and methods of production thereof
granted -
US 9283300
Use of midkine protein and the protein-containing medical device
granted -
US 9283194
Methods for protease assisted protein delivery
granted -
US 9278112
Citrate containing beverage
granted -
US 9278923
Pro-neurogenic compounds
granted -
US 9278113
Titanium dioxide nanotubes for production and delivery of nitric oxide and methods for production thereof
granted -
US 9278068
Vesicle compositions
granted -
US 9272055
Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
granted -
US 9273284
Method for generating potent dendritic cells
granted -
US 9273288
Pseudoinfectious flavivirus and uses thereof
granted -
US 9272991
Eicosanoid derivatives
granted -
US 9272034
Treatment of conditions related to shock
granted -
US 9271949
Compositions comprising acidic extracts of mastic gum
granted -
US 9273277
Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same
granted -
US 9265844
Protease degradable polypeptides and uses thereof
granted -
US 9267947
Compositions and methods for preventing or treating Burkholderia infection
granted -
US 9266931
Modified vitamin K-dependent polypeptides
granted -
US 9267139
Compositions and methods for treating musculoskeletal diseases and disorders
granted -
US 9267112
Adenovirus isolated from Titi Monkeys
granted -
US 9266901
Compositions and methods for treating cancer
granted -
US 9260510
Pertussis antibodies and uses thereof
granted -
US 9260493
Transducible delivery of nucleic acids using modified dsRNA binding domains
granted -
US 9259488
Anti-C3d antibody conjugates and methods of detecting complement activation
granted -
US 9259510
System and method for forming bone, ligament, and bone-ligament constructs
granted -
US 9259465
Methods and compositions for inhibiting diseases of the central nervous system
granted -
US 9260371
Compositions and methods for modification of biomolecules
granted -
US 9259407
Nanoemulsion therapeutic compositions and methods of using the same
granted -
US 9255260
Cytotoxic ribonuclease variants
granted -
US 9254280
Medical food for cognitive decline
granted -
US 9255155
Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
granted -
US 9254310
Therapeutic and cosmetic uses and applications of calreticulin
granted -
US 9249225
Single chain variable fragment anti-CD133 antibodies and uses thereof
granted -
US 9248161
Method for therapeutic replenishment and enrichment of ocular surface lubrication
granted -
US 9248131
Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
granted -
US 9248147
Methods for endoscopic mucosal resection and endoscopic submucosal dissection
granted -
US 9250239
Compositions and methods for detecting microbial infections
granted -
US 9249424
Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
granted -
US 9241906
Materials and methods for delivering compositions to selected tissues
granted -
US 9245290
Caspase inhibitors and uses thereof
granted -
US 9244082
Detection and treatment of LRP4-associated neurotransmission disorders
granted -
US 9243351
Fabrication of biscrolled fiber using carbon nanotube sheet
granted -
US 9243239
Purification of cystathionine beta-synthase
granted -
US 9243057
Antibodies for botulinum neurotoxins
granted -
US 9242014
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
granted -
US 9242000
Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory